'You just walked into the road'
"People who are fully sighted are actually blind to the needs of people with a visual impairment," says a Hampshire mayor, adding "that needs to change".
The Mayor and Mayoress of Eastleigh have been shopping in the town's centre wearing goggles designed to impair their vision.
They want to improve accessibility for those living with a visual impairment (VI) and raise awareness among other town councils.
Dave and Jean Pragnell spent more than an hour shopping to try to understand what people living with VI experience.
The goggles they wore were designed to mimic sight loss caused by Retinitis Pigmentosa, a genetic condition also described as pin-hole vision.
Rob Hiley, who also accompanied the mayor on his shopping spree, was born with the condition but didn't notice his vision deteriorate until he was 45.
Now 72, he says what he sees is similar to the tunnel-vision goggles worn by the mayor: "I think it's fantastic and long overdue that people in authority actually take an interest in people with a visual impairment."
With the help of her grandchildren, the mayoress walked around town wearing goggles mimicking diabetic retinopathy; a complication of diabetes which damages the retina.
She described the experience as having "very blurry vision with large dark floaters".
"Eastleigh was not the easiest place for a person with a sight loss to move about as there are so many things on the pavements," she said.
The goggles were supplied by local charity OpenSight which supports people in Hampshire with VI.
CEO Chris Dixon, who joined the mayor on his experience, said people living with VI find accessing the community a real challenge: "It's really important for us to be able to demonstrate those challenges and to try and get that empathy and awareness for the community to try and help."
During the walk Mr Pragnell highlighted areas of navigation he found difficult, such as the lack of tactile pavements, which indicate crossings, and floral planters: "They [planters] look great for people that can see, but unfortunately they're right in the way of people with sight impairment. We need to rethink that sort of thing."
He added that all council officers needed to do put the goggles on and experience what he did.
"Without it, they cannot do their jobs properly," he said.
You can follow BBC Hampshire & Isle of Wight on Facebook, X, or Instagram.
Goggles 'give back' sight to Maisy
Goggles help blind girl 'see' animals again
Blind opera singer's concern over pothole danger
Press Pack: How books are helping blind children experience stories through touch
'Learning guitar helped me cope with going blind'
Eastleigh Borough Council
Mayor of Eastleigh
OpenSight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space. Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought forward more than a dozen programs from discovery into clinical development, and he has developed multiple pioneering approved medicines such as Sotyktu, Stelara, and Tremfya. 'Dr. Rose joins the Nkarta team at a critical threshold as we discover the power of our NK cell platform to treat autoimmune diseases,' said Paul J. Hastings, CEO of Nkarta. 'He is an enterprise leader with a deep clinical background in rheumatology and immunology that's ideally suited to maximize the potential of our allogeneic NK cell platform. Shawn's proven track record as an expert clinician gives me full confidence that he will hit the ground running on day one and meaningfully advance our work in the clinic.' Dr. Rose most recently served as Chief Development Officer, Immunology, at Vividion Therapeutics, working to expand their portfolio by advancing previously undruggable targets in immunology. He also served as interim CMO and Head of Clinical Development at Magenta Therapeutics, working on cell-based therapeutic approaches for patients with cancer, genetic disorders and immune-mediated inflammatory diseases. Dr. Rose also held multiple clinical and development leadership roles at Annexon Biosciences, Janssen Pharmaceuticals, and Bristol-Myers Squibb. He did his postdoctoral research training and clinical training in Internal Medicine and Rheumatology at the Northwestern University Feinberg School of Medicine. 'I am thrilled to join Nkarta to advance innovative cell therapies for patients,' said Dr. Rose. 'I strongly believe that Nkarta's allogeneic NK cell platform has the potential to be a transformational approach for patients with immune-mediated inflammatory disease. I look forward to working closely with Paul and the broader Nkarta team on developing more treatment options for patients.' During the transition, Dr. Rose will work with Dr. Shook, who will remain on as a consultant through July 11. 'Dave was an early pioneer of NK cell therapy while working under Nkarta's scientific founder, Dario Campana, at St. Jude Children's Research Hospital, and he has tirelessly pursued options that were more convenient for patients with safety utmost in mind,' Hastings said. 'Dave has devoted much of his career to make important contributions to the advancement of natural killer cell therapy, leading our early clinical work in cancer and overseeing key aspects of our strategic shift into a new disease area with agility and flexibility. But Dave is a dedicated oncologist, and he has decided to return to the field he loves. He is a fearless advocate for patients and their well-being and a very good friend who will be missed.' About NKX019NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed chimeric antigen receptor (CAR) for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Nkarta is evaluating NKX019 in multiple autoimmune conditions. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at Cautionary Note on Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," 'plans,' 'potential,' "projects,' 'would' and "future" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include, but are not limited to, statements concerning Nkarta's expectations regarding any or all of the following: Nkarta's position, plans, strategies, and timelines for the continued and future clinical development and commercial potential of NKX019 (including the future availability and disclosure of clinical data and other updates from Nkarta's clinical trials). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Nkarta's limited operating history and historical losses; Nkarta's lack of any products approved for sale and its ability to achieve profitability; the risk that the results of preclinical studies and early-stage clinical trials may not be predictive of future results; Nkarta's ability to raise additional funding to complete the development and any commercialization of its product candidates; Nkarta's dependence on the clinical success of NKX019; that Nkarta may be delayed in initiating, enrolling patients in or completing its clinical trials; competition from third parties that are developing products for similar uses; Nkarta's ability to obtain, maintain and protect its intellectual property; Nkarta's dependence on third parties in connection with manufacturing, clinical trials and pre-clinical studies; the complexity of the manufacturing process for CAR NK cell therapies; and the success of Nkarta's recent (and any future) cost containment measures. These and other risks and uncertainties are described more fully in Nkarta's filings with the Securities and Exchange Commission ('SEC'), including the 'Risk Factors' section of Nkarta's Annual Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 14, 2025, and Nkarta's other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Nkarta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Nkarta Media/Investor Contact:Nadir MahmoodNkarta, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
5 days ago
- Associated Press
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ('Ocugen' or the 'Company') (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a licensing agreement with a well-established leader in the pharmaceutical and healthcare sector in Korea, for exclusive Korean rights to OCU400—Ocugen's novel modifier gene therapy for retinitis pigmentosa (RP). Pursuant to the term sheet, under the license agreement Ocugen will receive upfront license fees and near-term development milestones equaling up to $11 million. The Company will be entitled to sales milestones of $1 million for every $15 million of net sales in Korea in addition to a royalty of 25% on net sales of OCU400 generated by Ocugen's partner. Additionally, Ocugen will manufacture commercial supply of OCU400 under terms of a supply agreement. There are an estimated 15,000 individuals in the Republic of Korea with RP. OCU400 provides the opportunity for our partner to help thousands of patients and become a leader in gene therapy in Korea. 'This regional licensing agreement is aligned with our business development strategy to partner with well-established companies in their respective countries and regions—leveraging their networks and know-how to treat as many RP patients as possible,' said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. 'A regional approach preserves Ocugen's rights to larger geographies to maximize total patient reach while also generating return for our shareholders.' Additional details will be available once the definitive agreement between the parties is executed, which is expected to occur within the next 60 days. Ocugen is currently advancing OCU400 through Phase 3 clinical development with a target Biologics License Application filing of mid-2026. About Ocugen, Inc. Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases and offer hope for patients across the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Discover more at and follow us on X and LinkedIn. Cautionary Note on Forward-Looking Statements Thispressreleasecontainsforward-lookingstatementswithinthemeaningofThePrivateSecuritiesLitigationReformActof1995,including,butnot limited to, statements regarding the terms of the definitive license and timing of a definitive agreement or if a definitive agreement will be executed at all or the anticipated benefits to Ocugen of the definitive license agreement, qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, 'believes,' 'potential,' 'proposed,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should,'or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including,butnotlimitedto, Contact: Tiffany Hamilton AVP, Head of Communications [email protected]
Yahoo
5 days ago
- Yahoo
Non-profit fears for future of blindness research if Donald Trump's budget passes
LAKE COUNTY, Ill. (WGN) — Proposed federal funding cuts are hitting home in Lake County, especially when it comes to the blind. The Foundation Fighting Blindness, a Maryland-based non-profit organization who organizes the Chicago Vision Walk, fears clinical trials and promising new treatments for blindness and retinal disease will be frozen or canceled if President Donald Trump's 'Big, Beautiful Bill' passes into law. 'Six years old was when I got the diagnosis,' Rich Idstein said. 'It's tough.' Idstein is a legally blind man who works at Ace Hardware in Libertyville. He suffers from Retinitis Pigmentosa, a blinding retinal disease with no cure. Idstein and his two brothers all suffer from the same disease, which gets progressively worse with age. At the age of 52, Idstein figures he has five-to-ten years left before he's completely blind, but he's hoping clinical trials through the National Institutes of Health will lead to new treatments. 'We are driving research for therapies. They're called gene therapies that can replace or fix that code,' said Ben Shaberman, Vice President of Communications for the Foundation Fighting Blindness (FFB). 'So, the cells in the retina work correctly, and vision can be saved or restored.' The problem is, under Trump's proposed budget, the NIH is facing a potential 40% funding cut to medical research, which would directly impact the dollars going toward the clinical trials that Idstein hopes can help cure the disease that's plagued he and his brothers. The FFB has raised nearly $1 billion over the past five decades for eye and vision research, but its mission could be severely impacted if Congress doesn't act. For more info on the FFB, visit their website: Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
